Market Place
Sourcing Support
Agenus Reports Q3 2024 Results & Advances BOT/BAL Development
12 Nov 2024 //
BUSINESSWIRE
Agenus to Provide Q32024 Financial Report & Corporate Update
05 Nov 2024 //
BUSINESSWIRE
Botensilimab/Balstilimab Data In Refractory Sarcomas Presented At ESMO
13 Sep 2024 //
BUSINESSWIRE
Botensilimab/Balstilimab Sarcoma Data To Be Presented At ESMO
09 Sep 2024 //
BUSINESSWIRE
Xencor Announces Autoimmune And Oncology Drug Candidates
09 Sep 2024 //
BUSINESSWIRE
Agenus Announces Appointment of Tom Harrison to Board of Directors
08 Aug 2024 //
BUSINESSWIRE
Agenus Reports Second Quarter 2024 Operational and Financial Results
08 Aug 2024 //
BUSINESSWIRE
Agenus Publishes Study On Botensilimab`s Activity In Resistant Cancers
07 Aug 2024 //
BUSINESSWIRE
BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific
05 Aug 2024 //
FIERCE BIOTECH
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
26 Jul 2024 //
BUSINESSWIRE
FDA Rejects Agenus` Accelerated Approval Plan For Cancer Combo
19 Jul 2024 //
FIERCE BIOTECH
Agenus Reports Phase 2 Data For BOT/BAL In MSS Colorectal Cancer
18 Jul 2024 //
BUSINESSWIRE
Significant Tumor Reductions in MSS Colon Cancer with Botensilimab/Balstilimab
28 Jun 2024 //
BUSINESSWIRE
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
23 May 2024 //
BUSINESSWIRE
Botensilimab Mss Crc Breakthrough: Balstilimab Data Presented Asco 2024
23 May 2024 //
BUSINESSWIRE
FDA Grants Agenus End-of-Phase 2 Meeting For BOT/BAL In mCRC
16 May 2024 //
BUSINESSWIRE
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
07 May 2024 //
BUSINESSWIRE
Agenus Reports First Quarter 2024 Results
07 May 2024 //
BUSINESSWIRE
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
28 Apr 2024 //
FOOL
Botensilimab/Balstilimab MSS CRC Data at ASCO 2024
24 Apr 2024 //
BUSINESSWIRE
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
23 Apr 2024 //
BUSINESSWIRE
Agenus: Ph1 mCRC Data, BOT/BAL Development Progress
12 Apr 2024 //
BUSINESSWIRE
Agenus Announces Reverse Stock Split
05 Apr 2024 //
PRESS RELEASE
Agenus Reports Fourth Quarter and Full Year 2023 Results
14 Mar 2024 //
BUSINESSWIRE
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
06 Mar 2024 //
BUSINESSWIRE
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Mar 2024 //
BUSINESSWIRE
Agenus to Provide Update and Fourth Quarter & Full Year 2023 Financial Report
29 Feb 2024 //
BUSINESSWIRE
Agenus to Participate in Leerink Partners Global Biopharma Conference
26 Feb 2024 //
BUSINESSWIRE
Agenus to Participate in B. Riley Healthcare Conference
04 Jan 2024 //
BUSINESSWIRE
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb
11 Dec 2023 //
BUSINESSWIRE
Agenus Reports Third Quarter 2023 Results
07 Nov 2023 //
BUSINESSWIRE
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
26 Oct 2023 //
BUSINESSWIRE
Agenus Unveils New and Updated Botensilimab Data in Colorectal
22 Oct 2023 //
BUSINESSWIRE
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab
10 Oct 2023 //
BUSINESSWIRE
Agenus To Host BOT/BAL Program Update at ESMO 2023
05 Oct 2023 //
BUSINESSWIRE
Agenus to trim its staff numbers and assets
24 Aug 2023 //
ENDPTS
Agenus Prioritizes Resources to Accelerate Registration of BOT/BAL Program
23 Aug 2023 //
BUSINESSWIRE
Agenus Reports Second Quarter 2023 Results
08 Aug 2023 //
BUSINESSWIRE
Agenus Botensilimab/Balstilimab Data in Sarcomas Selected for Presentation
28 Jul 2023 //
BUSINESSWIRE
Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
26 Jul 2023 //
BUSINESSWIRE
Agenus Expands Executive Leadership Team
20 Jul 2023 //
BUSINESSWIRE
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
05 Jun 2023 //
BUSINESSWIRE
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
09 May 2023 //
BUSINESSWIRE
Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI
03 May 2023 //
BUSINESSWIRE
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab
17 Apr 2023 //
BUSINESSWIRE
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
30 Mar 2023 //
BUSINESSWIRE
Agenus gets boost for combo drug, this time in ovarian cancer
27 Mar 2023 //
FIERCE BIOTECH
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
Agenus Cancels Conference Call to Discuss Minority Cash Holdings
12 Mar 2023 //
GLOBENEWSWIRE
Agenus Schedules Conference Call to Discuss Minority Cash Holdings at SVB
11 Mar 2023 //
GLOBENEWSWIRE
Agenus to Present Botensilimab Data in Oral Plenary Session at Annual Meeting
28 Feb 2023 //
GLOBENEWSWIRE
Agenus to Provide Fourth Quarter & Full Year 2022 Financial Report
28 Feb 2023 //
GLOBENEWSWIRE
Agenus to Participate in February Investor Conferences
26 Jan 2023 //
GLOBENEWSWIRE
Combo may offer route back for Agenus` cervical cancer drug
24 Jan 2023 //
FIERCE BIOTECH
Agenus Presents Data Demonstrating Durable Responses of Botensilimab/Balstilimab
23 Jan 2023 //
GLOBENEWSWIRE
Agenus to Participate at B Riley Securities 2023 Virtual Oncology Conference
10 Jan 2023 //
GLOBENEWSWIRE
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
21 Dec 2022 //
GLOBENEWSWIRE
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab
17 Nov 2022 //
GLOBENEWSWIRE
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
16 Nov 2022 //
GLOBENEWSWIRE
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab
14 Nov 2022 //
GLOBENEWSWIRE
